The University of Wisconsin System, through its University of Wisconsin - Madison division, was awarded a $218,089 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to conduct research on the mechanism and treatment of Wilms tumors caused by CTR9 mutations. The research aims to enhance the understanding of the pathogenesis of Wilms tumor, the most common pediatric cancer of the urinary tract, and establish an experimental platform for identifying effective therapies. Key objectives include delineating how the exon 9 deletion in the CTR9 gene disrupts transcriptional elongation and alternative mRNA splicing, as well as examining if the exon 9 deletion renders cells sensitive to inhibitors of the EZH2 enzyme and splicing machinery. The project will be carried out over a two-year period from February 1, 2025 to January 31, 2027.
Generated 3/4/25, 7:24 AM